Tech Center 1600 • Art Units: 1618
This examiner grants 23% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17908766 | Radionuclide Tracers of 1-Amino-3,4-Difluorocyclopentane-1-Carboxylic Acid, Derivatives, and Uses Thereof | Final Rejection | Emory University |
| 19345876 | IMPROVED LOCAL ANESTHETIC SOLUTION FOR DENTAL AND/OR CONTRAST MEDIA USE | Non-Final OA | Neocaine, LLC |
| 17308599 | CATIONIC MUCIC ACID POLYMER-BASED DELIVERY SYSTEMS | Non-Final OA | California Institute Of Technology |
| 19273752 | ORAL FORMULATIONS OF DEURUXOLITINIB | Final Rejection | Sun Pharmaceutical Industries, Inc. |
| 17445285 | ENHANCING SUBCUTANEOUS INJECTION AND TARGET TISSUE ACCUMULATION OF NANOPARTICLES VIA CO-ADMINISTRATION WITH MACROPINOCYTOSIS INHIBITORY NANOPARTICLES (MINP) | Non-Final OA | Northwestern University |
| 17437417 | INTRACELLULAR DELIVERY AND MITOCHONDRIAL TARGETING BY FLUORINATION | Final Rejection | The Texas A&M University System |
| 17275658 | RADIOLABELED PABA AND DERIVATIVES THEREOF FOR USE AS FUNCTIONAL RENAL IMAGING AGENTS | Final Rejection | The Johns Hopkins University |
| 18766083 | TMEM-MCD IN THE MINIMALLY INVASIVE ASSESSMENT OF THE ACTIVITY STATUS OF TMEM IN ITS DISSEMINATION OF TUMOR CELLS | Final Rejection | Montefiore Medical Center |
| 17403157 | COSMETIC COMPOSITIONS | Non-Final OA | L'Oreal |
| 17063423 | Liposomal-gold nanoparticles for drug delivery into the brain | Non-Final OA | University of Puerto Rico |
| 18904575 | Compositions and Methods for Targeting Lipid Nanoparticle Therapeutics to Stem Cells | Non-Final OA | The Trustees of the University of Pennsylvania |
| 19005409 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | Final Rejection | LYKOS THERAPEUTICS, INC. |
| 19005427 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | Final Rejection | LYKOS THERAPEUTICS, INC. |
| 19005376 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | Final Rejection | LYKOS THERAPEUTICS, INC. |
| 18611564 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | Final Rejection | LYKOS THERAPEUTICS, INC. |
| 16494568 | NON-VIRAL, NON-CATIONIC NANOPARTICLES AND USES THEREOF | Final Rejection | Children's Medical Center Corporation |
| 18166390 | METHODS AND COMPOSITION FOR DYE-BASED ENCODING AND QUANTIFICATION | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 17622117 | IRON(III) AND GALLIUM(III) METAL ORGANIC POLYHEDRA, METHODS OF MAKING SAME, AND USES THEREOF | Final Rejection | The Research Foundation for The State University of New York |
| 15516407 | LIPOSOMES-CONTAINING ANTIFOULING COMPOSITIONS AND USES THEREOF | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 18424697 | STEREOCOMPLEX OF OLIGOLACTIC ACID CONJUGATES IN MICELLES FOR IMPROVED PHYSICAL STABILITY AND ENHANCED ANTITUMOR EFFICACY | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17096268 | COMPOSITIONS AND METHODS OF TREATING THERAPY RESISTANT CANCER AND USES THEREOF | Final Rejection | The Methodist Hospital |
| 18772309 | Ophthalmic dye composition | Non-Final OA | Vitreq B.V. |
| 18445604 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof C | Non-Final OA | Nammi Therapeutics, Inc. |
| 18640861 | ANTIMICROBIAL AND DRUG-NEUTRALIZING COMPOSITION | Non-Final OA | Aseptic Health, LLC |
| 17536193 | Composition and A Method For Diagnosing And Treating Bacterial Infection | Final Rejection | Hong Kong Centre for Cerebro-Cardiovascular Health Engineering Limited |
| 18415412 | CHITOSAN SUPERFINE FIBER SYSTEMS | Non-Final OA | Tricol Biomedical, Inc. |
| 17753312 | SYSTEMS AND METHODS FOR HIGH-THROUGHPUT SCREENING AND ANALYSIS OF DRUG DELIVERY SYSTEMS IN VITRO | Non-Final OA | Trustees of Tufts College |
| 17554823 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | Final Rejection | Trustees of Tufts College |
| 17614753 | MACROPHAGE IMAGING AGENT | Non-Final OA | JSR CORPORATION |
| 17775217 | BIOMARKER OF DRUG-INDUCED CELLULAR TOXICITY AND DEPRESSION | Non-Final OA | Randox Laboratories Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy